-
-
-
-
-
-
-
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
-
-
-
-
-
-
-
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
-
-
-
-
-
-
-
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
-
-
-
-
-
-
Omega Therapeutics (OMGA) Appoints Chris Schade to its Board
-
-
-
-
-
-
-
Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma
-
-
-
-
-
-
-
Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

